Literature DB >> 11195419

NCCN Practice Guidelines for Acute Myelogenous Leukemia.

F R Appelbaum1, M R Baer, M H Carabasi, S E Coutre, H P Erba, E Estey, M J Glenn, E H Kraut, P Maslak, M Millenson, C B Miller, H I Saba, R Stone, M S Tallman.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 11195419

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  11 in total

1.  High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China.

Authors:  Bin-Tao Huang; Qing-Chun Zeng; Jessica Yu; Xiao-Li Liu; Zhen Xiao; Hong-Qian Zhu
Journal:  Med Oncol       Date:  2011-01-22       Impact factor: 3.064

2.  Analysis of efficacy and cost-effectiveness of high-dose arabinoside versus daunorubicin chemotherapy in older adult patients with acute myeloid leukemia by cytogenetic risk profile: retrospective review from China.

Authors:  Bin-Tao Huang; Yu Wang; Qing-Feng Du; Jun Yang; Jessica Yu; Qing-Chun Zeng; Na Xu; Jin-Fang Zhang; Lu-Lu Xu; Xu-Jing Luo; Yong-Qiang Wei; Xiao-Li Liu
Journal:  Int J Hematol       Date:  2011-03-10       Impact factor: 2.490

3.  Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.

Authors:  Prajwal Chaitanya Boddu; Hagop M Kantarjian; Farhad Ravandi; Guillermo Garcia-Manero; Srdan Verstovsek; Elias J Jabbour; Koichi Takahashi; Kapil Bhalla; Marina Konopleva; Courtney D DiNardo; Maro Ohanian; Naveen Pemmaraju; Nitin Jain; Sherry Pierce; William G Wierda; Jorge E Cortes; Tapan M Kadia
Journal:  Cancer       Date:  2017-04-07       Impact factor: 6.860

Review 4.  Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.

Authors:  Margaret L Gulley; Thomas C Shea; Yuri Fedoriw
Journal:  J Mol Diagn       Date:  2009-12-03       Impact factor: 5.568

5.  Ikaros expression sensitizes leukemic cells to the chemotherapeutic drug doxorubicin.

Authors:  Licai He; Shenmeng Gao; Zhenfeng Zhu; Shang Chen; Haihua Gu
Journal:  Oncol Lett       Date:  2016-06-07       Impact factor: 2.967

6.  Standard intensive chemotherapy is less effective and far more toxic than attenuated induction and post-induction regimen in elderly patients with acute myeloid leukemia.

Authors:  Bin-Tao Huang; Wei-Hong Zhao; Qing-Chun Zeng; Bing-Sheng Li; Rui-lin Chen
Journal:  Med Oncol       Date:  2014-04-18       Impact factor: 3.064

7.  Improving the outcomes of elderly patients with acute myeloid leukemia in a Brazilian University Hospital.

Authors:  Alex Freire Sandes; Juliana Correa da Costa Ribeiro; Rodrigo S Barroso; Maria R R Silva; Maria L L F Chauffaille
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

8.  Interpreting clinical assays for histone deacetylase inhibitors.

Authors:  Nadine Martinet; Philippe Bertrand
Journal:  Cancer Manag Res       Date:  2011-05-09       Impact factor: 3.989

9.  Early B-cell factor 3 (EBF3) is a novel tumor suppressor gene with promoter hypermethylation in pediatric acute myeloid leukemia.

Authors:  Yan-Fang Tao; Li-Xiao Xu; Jun Lu; Shao-Yan Hu; Fang Fang; Lan Cao; Pei-Fang Xiao; Xiao-Juan Du; Li-Chao Sun; Zhi-Heng Li; Na-Na Wang; Guang-Hao Su; Yan-Hong Li; Gang Li; He Zhao; Yi-Ping Li; Yun-Yun Xu; Hui-Ting Zhou; Yi Wu; Mei-Fang Jin; Lin Liu; Xue-Ming Zhu; Jian Ni; Jian Wang; Feng Xing; Wen-Li Zhao; Jian Pan
Journal:  J Exp Clin Cancer Res       Date:  2015-01-22

10.  Metallothionein III (MT3) is a putative tumor suppressor gene that is frequently inactivated in pediatric acute myeloid leukemia by promoter hypermethylation.

Authors:  Yan-Fang Tao; Li-Xiao Xu; Jun Lu; Lan Cao; Zhi-Heng Li; Shao-Yan Hu; Na-Na Wang; Xiao-Juan Du; Li-Chao Sun; Wen-Li Zhao; Pei-Fang Xiao; Fang Fang; Yan-Hong Li; Gang Li; He Zhao; Yi-Ping Li; Yun-Yun Xu; Jian Ni; Jian Wang; Xing Feng; Jian Pan
Journal:  J Transl Med       Date:  2014-06-25       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.